全文获取类型
收费全文 | 256650篇 |
免费 | 40732篇 |
国内免费 | 6819篇 |
专业分类
耳鼻咽喉 | 6392篇 |
儿科学 | 7069篇 |
妇产科学 | 3842篇 |
基础医学 | 15407篇 |
口腔科学 | 3279篇 |
临床医学 | 37530篇 |
内科学 | 63741篇 |
皮肤病学 | 9199篇 |
神经病学 | 20122篇 |
特种医学 | 11070篇 |
外国民族医学 | 8篇 |
外科学 | 55036篇 |
综合类 | 15051篇 |
现状与发展 | 84篇 |
一般理论 | 38篇 |
预防医学 | 14421篇 |
眼科学 | 6280篇 |
药学 | 11168篇 |
56篇 | |
中国医学 | 4562篇 |
肿瘤学 | 19846篇 |
出版年
2024年 | 861篇 |
2023年 | 5646篇 |
2022年 | 3585篇 |
2021年 | 6774篇 |
2020年 | 8583篇 |
2019年 | 4709篇 |
2018年 | 10141篇 |
2017年 | 9984篇 |
2016年 | 11193篇 |
2015年 | 12471篇 |
2014年 | 20680篇 |
2013年 | 21528篇 |
2012年 | 14296篇 |
2011年 | 14452篇 |
2010年 | 16778篇 |
2009年 | 19727篇 |
2008年 | 12662篇 |
2007年 | 10805篇 |
2006年 | 12908篇 |
2005年 | 9455篇 |
2004年 | 7671篇 |
2003年 | 6447篇 |
2002年 | 5980篇 |
2001年 | 6822篇 |
2000年 | 5348篇 |
1999年 | 4915篇 |
1998年 | 4416篇 |
1997年 | 4134篇 |
1996年 | 3901篇 |
1995年 | 3641篇 |
1994年 | 2324篇 |
1993年 | 1877篇 |
1992年 | 1987篇 |
1991年 | 1995篇 |
1990年 | 1574篇 |
1989年 | 1658篇 |
1988年 | 1443篇 |
1987年 | 1292篇 |
1986年 | 1262篇 |
1985年 | 1039篇 |
1984年 | 766篇 |
1983年 | 688篇 |
1982年 | 623篇 |
1981年 | 497篇 |
1980年 | 460篇 |
1979年 | 464篇 |
1978年 | 433篇 |
1977年 | 479篇 |
1975年 | 365篇 |
1972年 | 376篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
目的 运用CT区分脾脏血管性病变与淋巴瘤。方法 回顾性分析20例经手术、穿刺病理学检查证实的脾脏病变的发病年龄、性别、脾脏指数、病变大小、数目、有无液化、钙化、强化幅度、强化方式等特征,并进行统计学分析。结果 20例脾脏病变中,11例血管性病变(6例海绵状血管瘤,3例窦岸细胞血管瘤,2例硬化性血管瘤样结节性转化),9例淋巴瘤;两组间发病年龄、病变大小、数目、有无液化、钙化等差异无统计学意义;两组间脾脏指数、动脉期强化幅度差异具有统计学意义(P<0.05)。5例海绵状血管瘤呈不均匀性强化,1例呈渐进性填充式强化,2例窦岸细胞血管瘤呈“雀斑征”,1例硬化性血管瘤样结节性转化呈“辐轮征”;9例淋巴瘤实质部分均呈均匀、轻中度强化。结论 脾脏血管性病变与淋巴瘤CT表现不同,CT有助于明确诊断。 相似文献
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
15.
16.
17.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
18.
19.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
20.